Last 47 quarters of trend data · Healthcare · Medical - Healthcare Plans
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 39.47 | 17.36 | 4.41 | — | 40.15 | 13.55 | 6.42 | — | 19.90 | 16.59 | 14.19 | — | 18.13 | 14.59 | 12.30 | — | 12.92 | 21.35 | 14.92 | — | 8.22 |
| — | +28.1% | -31.3% | — | +101.8% | -18.3% | -54.7% | — | +9.8% | +13.7% | +15.4% | — | +40.3% | -31.7% | -17.6% | — | +57.2% | -12.2% | -9.0% | — | -20.2% | |
| P/S Ratio | 0.36 | 0.29 | 0.13 | 0.24 | 0.24 | 0.23 | 0.25 | 0.26 | 0.33 | 0.38 | 0.35 | 0.53 | 0.57 | 0.52 | 0.57 | 0.72 | 0.68 | 0.63 | 0.58 | 0.71 | 0.58 |
| — | +28.9% | -47.0% | -9.6% | -26.0% | -40.3% | -29.9% | -50.5% | -43.0% | -27.0% | -37.7% | -26.1% | -15.8% | -16.8% | -1.5% | +1.1% | +17.2% | -9.4% | -11.9% | -0.2% | -15.8% | |
| P/B Ratio | 2.65 | 2.49 | 1.12 | 1.74 | 1.69 | 1.61 | 1.79 | 1.86 | 2.17 | 2.70 | 2.60 | 3.44 | 3.55 | 3.31 | 3.66 | 4.19 | 3.79 | 3.84 | 3.62 | 3.70 | 3.09 |
| — | +54.4% | -37.4% | -6.7% | -22.1% | -40.1% | -31.0% | -45.8% | -38.8% | -18.6% | -29.1% | -17.9% | -6.3% | -13.6% | +1.3% | +13.0% | +22.6% | -0.6% | -5.5% | -6.2% | -11.6% | |
| P/FCF | 124.34 | — | 4.62 | — | 9.40 | 6.38 | 33.85 | — | 5.53 | 10.26 | 42.73 | — | 14.81 | 4.80 | 2.36 | — | 1.89 | 21.87 | 1981.17 | — | 5.01 |
| — | — | -86.4% | — | +69.8% | -37.8% | -20.8% | — | -62.6% | +113.6% | +1712.5% | — | +683.0% | -78.0% | -99.9% | — | -62.3% | -95.3% | — | — | -43.1% | |
| EV / EBITDA | 24.31 | 9.11 | 4.22 | — | 30.96 | 10.20 | 5.50 | — | 13.14 | 11.47 | 10.01 | — | 10.77 | 8.71 | 8.10 | 125.97 | 9.71 | 12.60 | 11.19 | 133.63 | 7.95 |
| — | -10.6% | -23.2% | — | +135.6% | -11.1% | -45.0% | — | +22.0% | +31.7% | +23.6% | — | +10.8% | -30.9% | -27.6% | -5.7% | +22.2% | -22.4% | -4.7% | — | +13.0% | |
| EV / EBIT | 38.10 | 12.05 | 4.23 | — | 35.00 | 10.83 | 5.67 | — | 14.35 | 12.27 | 10.74 | — | 11.85 | 9.38 | 8.60 | 555.04 | 10.49 | 13.71 | 12.17 | 643.42 | 8.38 |
| — | +11.3% | -25.5% | — | +143.9% | -11.8% | -47.2% | — | +21.1% | +30.9% | +24.8% | — | +13.0% | -31.6% | -29.3% | -13.7% | +25.3% | -23.7% | -4.7% | — | +13.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.5% | 13.5% | 15.0% | 11.7% | 14.3% | 14.9% | 17.4% | 13.1% | 14.5% | 15.2% | 15.2% | 13.9% | 17.7% | 17.7% | 18.3% | 17.2% | 19.4% | 19.3% | 18.1% | 17.0% | 20.4% |
| — | -9.7% | -13.7% | -11.0% | -1.9% | -2.3% | +14.6% | -5.7% | -17.8% | -14.0% | -17.0% | -19.1% | -8.6% | -8.1% | +0.8% | +0.8% | -5.1% | +13.9% | +11.1% | +14.1% | -8.2% | |
| Operating Margin | 1.1% | 3.3% | 4.0% | -3.2% | 0.3% | 2.2% | 5.1% | -3.1% | 2.2% | 3.1% | 3.3% | -2.3% | 4.1% | 4.7% | 6.0% | -0.3% | 5.7% | 4.8% | 5.1% | -0.3% | 7.6% |
| — | +49.3% | -22.4% | -2.4% | -84.7% | -26.9% | +53.5% | -32.4% | -47.4% | -34.8% | -44.0% | -586.2% | -27.9% | -1.5% | +17.7% | -11.3% | -24.9% | +27.2% | -1.2% | +87.2% | -14.9% | |
| Net Margin | 0.9% | 1.7% | 3.0% | -2.4% | 0.6% | 1.7% | 3.9% | -2.4% | 1.6% | 2.3% | 2.5% | -2.0% | 3.1% | 3.6% | 4.6% | -0.1% | 5.2% | 2.9% | 3.9% | -0.1% | 7.0% |
| — | +0.8% | -22.8% | -3.2% | -63.4% | -26.8% | +54.8% | -16.0% | -48.1% | -35.9% | -46.0% | -2960.5% | -39.9% | +21.9% | +19.4% | -0.3% | -25.5% | +3.3% | -3.2% | +95.4% | +5.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.0% | 3.7% | 6.5% | -4.4% | 1.1% | 3.0% | 7.3% | -4.1% | 2.8% | 4.1% | 4.6% | -3.2% | 4.9% | 5.7% | 7.7% | -0.1% | 7.5% | 4.5% | 5.9% | -0.1% | 9.8% |
| — | +21.1% | -10.2% | -7.7% | -62.2% | -26.8% | +59.3% | -25.3% | -43.1% | -27.9% | -41.1% | -3328.8% | -34.6% | +26.8% | +30.9% | -9.5% | -23.7% | +11.4% | -0.3% | +95.3% | +10.8% | |
| ROA | 2.5% | 1.2% | 2.3% | -1.6% | 0.4% | 1.1% | 2.6% | -1.4% | 1.0% | 1.4% | 1.5% | -1.1% | 1.5% | 1.7% | 2.5% | -0.0% | 2.4% | 1.5% | 2.0% | -0.0% | 3.7% |
| — | +14.5% | -10.9% | -12.4% | -59.4% | -20.6% | +67.4% | -36.7% | -35.2% | -21.4% | -39.3% | -3220.5% | -39.5% | +15.4% | +23.2% | -1.9% | -33.3% | -4.1% | -10.6% | +95.8% | +5.4% | |
| ROIC | 4.1% | 3.8% | 4.4% | -2.9% | 0.3% | 2.0% | 4.6% | -2.6% | 1.9% | 2.8% | 3.1% | -2.5% | 6.3% | 7.0% | 6.6% | -0.3% | 5.3% | 3.6% | 3.7% | -0.2% | 5.8% |
| — | +86.3% | -5.6% | -13.4% | -84.0% | -29.0% | +47.8% | -5.3% | -69.4% | -59.3% | -52.2% | -664.7% | +17.4% | +92.9% | +77.4% | -68.3% | -7.6% | +13.2% | -21.6% | +91.0% | -34.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.73 | 0.74 | 0.75 | 0.73 | 0.68 | 0.69 | 0.75 | 0.75 | 0.74 | 0.77 | 0.82 | 0.75 | 0.69 | 0.70 | 0.70 | 0.76 | 0.65 | 0.83 | 0.85 | 0.82 | 0.75 |
| — | +7.4% | +0.5% | -2.2% | -8.2% | -10.8% | -8.5% | -0.8% | +7.1% | +10.9% | +16.9% | -1.7% | +6.2% | -16.0% | -17.5% | -6.9% | -13.8% | +71.2% | +65.2% | +57.8% | +52.6% | |
| Debt / EBITDA | 5.68 | 9.38 | 7.89 | — | 40.41 | 13.49 | 7.14 | — | 14.83 | 11.27 | 10.72 | — | 8.88 | 7.95 | 6.40 | 83.35 | 7.00 | 9.63 | 9.13 | 101.73 | 6.69 |
| — | -30.5% | +10.5% | — | +172.4% | +19.7% | -33.4% | — | +67.1% | +41.9% | +67.6% | — | +26.8% | -17.5% | -29.9% | -18.1% | +4.6% | +26.3% | +54.4% | — | +67.8% | |
| Current Ratio | 0.72 | 1.74 | 1.26 | 0.72 | 0.78 | 0.75 | 0.71 | 0.44 | 0.58 | 0.74 | 0.77 | 0.56 | 0.85 | 0.90 | 0.88 | 0.58 | 0.84 | 0.74 | 0.71 | 0.50 | 0.63 |
| — | +131.1% | +78.4% | +65.5% | +33.8% | +1.5% | -7.4% | -22.3% | -31.4% | -17.0% | -13.2% | -2.7% | +1.1% | +20.4% | +24.5% | +16.7% | +33.6% | +26.9% | +18.6% | -23.2% | -29.6% | |
| Quick Ratio | 0.72 | 1.74 | 1.26 | 0.72 | 0.78 | 0.75 | 0.71 | 0.44 | 0.58 | 0.74 | 0.77 | 0.56 | 0.85 | 0.90 | 0.88 | 0.58 | 0.84 | 0.74 | 0.71 | 0.50 | 0.63 |
| — | +131.1% | +78.4% | +65.5% | +33.8% | +1.5% | -7.4% | -22.3% | -31.4% | -17.0% | -13.2% | -2.7% | +1.1% | +20.4% | +24.5% | +16.7% | +33.6% | +26.9% | +18.6% | -23.2% | -29.6% | |
| Interest Coverage | 3.30 | 5.83 | 9.18 | -6.02 | 1.64 | 5.60 | 11.30 | -4.48 | 4.76 | 6.36 | 7.23 | -3.21 | 10.53 | 11.43 | 15.13 | 0.30 | 13.75 | 12.13 | 14.51 | 0.30 | 19.76 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HUM stock.
Humana Inc.'s current P/E is 39.5x. The average P/E over the last 3 quarters is 20.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Humana Inc.'s current operating margin is 1.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Humana Inc.'s business trajectory between earnings reports.